Andrew Koustenis

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo et al. · Clinical Cancer Research · 2017 · 683 citations · Full text

Medicine, Oncology, Pharmacology +17

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

Suresh Senan, Anthony Brade, Lu-hua Wang et al. · Journal of Clinical Oncology · 2016 · 437 citations · Full text

Medicine, Oncology, Radiation Oncology +14

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Ralph Zinner, Coleman K. Obasaju, David R. Spigel et al. · Journal of Thoracic Oncology · 2014 · 173 citations · Full text

Medicine, Oncology, Pharmacology +5

MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.

Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo et al. · Journal of Clinical Oncology · 2016 · 67 citations

Medicine, Oncology, Pharmacology +13

Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

Jonathan W. Goldman, Peipei Shi, Martin Reck et al. · Clinical Lung Cancer · 2015 · 52 citations · Full text

Medicine, Oncology, Pharmacology +15